Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?   

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Johns Hopkins University School of Medicine
There is no long term overall survival benefit ass...
Medical Oncologist at Saint Louise Regional Hospital
One might argue that although the benefit is modes...
Sign in or Register to read more